Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven B Bradfute

Showing results (1-10 of 90) with videos related to

Pageof 9
Sort By:
Expert Opinion on Investigational Drugs|November 15, 2016
The early clinical development of Ebola virus treatmentsSteven B Bradfute
Expert Opinion on Drug Discovery|December 28, 2021
The discovery and development of novel treatment strategies for filovirusesSteven B Bradfute
The Lancet. Infectious Diseases|November 8, 2015
Duration of immune responses after Ebola virus vaccinationSteven B Bradfute
Antiviral Research|December 25, 2022
History and impact of the mouse-adapted Ebola virus modelSteven B Bradfute
Viruses|October 14, 2011
Correlates of immunity to filovirus infectionSteven B Bradfute, Sina Bavari
Current Pharmaceutical Design|March 12, 2015
Staphylococcus aureus: Current State of Prevalence, Impact, and Vaccine DevelopmentMeghan Brett, Steven B Bradfute
Viruses|February 28, 2023
The Host Non-Coding RNA Response to Alphavirus InfectionMahgol Behnia, Steven B Bradfute
Antiviral Research|January 15, 2020
The use of mice lacking type I or both type I and type II interferon responses in research on hemorrhagic fever viruses. Part 1: Potential effects on adaptive immunity and response to vaccinationElizabeth C Clarke, Steven B Bradfute
Viruses|October 2, 2015
Filoviruses: One of These Things is (not) Like the OtherScott M Anthony, Steven B Bradfute
The Lancet. Infectious Diseases|June 14, 2017
Advances in Ebola virus vaccinationElizabeth C Clarke, Steven B Bradfute
Pageof 9

Showing results (1-10 of 90) with videos related to

Sort By:
Pageof 9
Expert Opinion on Investigational Drugs|November 15, 2016
The early clinical development of Ebola virus treatmentsSteven B Bradfute
Expert Opinion on Drug Discovery|December 28, 2021
The discovery and development of novel treatment strategies for filovirusesSteven B Bradfute
The Lancet. Infectious Diseases|November 8, 2015
Duration of immune responses after Ebola virus vaccinationSteven B Bradfute
Antiviral Research|December 25, 2022
History and impact of the mouse-adapted Ebola virus modelSteven B Bradfute
Viruses|October 14, 2011
Correlates of immunity to filovirus infectionSteven B Bradfute, Sina Bavari
Current Pharmaceutical Design|March 12, 2015
Staphylococcus aureus: Current State of Prevalence, Impact, and Vaccine DevelopmentMeghan Brett, Steven B Bradfute
Viruses|February 28, 2023
The Host Non-Coding RNA Response to Alphavirus InfectionMahgol Behnia, Steven B Bradfute
Antiviral Research|January 15, 2020
The use of mice lacking type I or both type I and type II interferon responses in research on hemorrhagic fever viruses. Part 1: Potential effects on adaptive immunity and response to vaccinationElizabeth C Clarke, Steven B Bradfute
Viruses|October 2, 2015
Filoviruses: One of These Things is (not) Like the OtherScott M Anthony, Steven B Bradfute
The Lancet. Infectious Diseases|June 14, 2017
Advances in Ebola virus vaccinationElizabeth C Clarke, Steven B Bradfute
Pageof 9